Alexandria Real Estate Equities, Inc. Continues its Generational Consequential Leadership as Pioneer of The Commercial Life Science Ecosystem and Second Most Active Early-Stage Life Science Investor in its New York City Life Science Cluster
Alexandria Real Estate Equities issued a press release highlighting its role as a pioneer in the commercial life science ecosystem and its status as the second most active early-stage life science investor in New York City. The release references historical value creation, including the 2025 acquisition of portfolio company Intra-Cellular Therapies by Johnson & Johnson for $14.6 billion and the earlier exit of Petra Pharmaceuticals to Eli Lilly.
Key figures
- Market cap
- $20.44 billion
- Operating properties rsf
- 35.8 million
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.